Pharmamel seeks to finance drug against hospital infection with EUR 6m, plans to go public by late 2024
Pharmamel busca financiar con EUR 6m fármaco contra infección hospitalaria y planea salir a bolsa hacia fines de 2024
Intel ID : 391919
|
||||
| Intel ID | 391919 | |||
| Value | ND | |||
| Native Currency | Euro (EUR) | |||
|
Financial Data - Pharmamel
(31 Dec 2021) |
Revenue: EUR 0,26m Net Debt: EUR 3,82m |
|||
| Date |
 |
|||
| Country | |
|||
| Geography | |
|||
| Subsector (Old TTR Sectors) |
|
|||
| Primary Subsector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|||
| Type |
|
|||
| Intel Grade |
 |
|||
| Source |
|
|||
| Tags | |
Issuer
| Name |
|
|||
| Subsector (Old TTR Sectors) |
|
|||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|||
| Country |
|
|||
| Website |
|
|||
| Description |
|
Radar
| Date | Title | Type | Intel Grade | Country | Subsector | ||
|
|
|
|
|
|
|
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.